Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A reduced activity of methylenetetrahydrofolate reductase (MTHFR) due to frequent C677T polymorphism affects DNA synthesis, repair and methylation and may be implicated in breast cancer risk.
We conducted a nested case-control study within a phase III prevention trial of tamoxifen. After a median follow-up of 81.2 months, 79 of the 5,408 hysterectomised women aged 35–70 years, who had received either tamoxifen 20 mg/day or placebo for 5 years, developed breast cancer. A total of 46 breast cancer cases and 80 unaffected controls matched to treatment allocation, years from randomization (±2 years) and age at randomization (±5 years), underwent genotyping for MTHFR C677T polymorphism using real time PCR.
The MTHFR 677 genotype frequencies for CC, CT, TT in breast cancer cases were 30%, 44% and 26%, respectively, and 35%, 51%, 14% in controls. We observed a borderline significant odds ratio of 2.51 (95% CI, 0.96–6.55) of breast cancer in subjects with 677TT genotype, with no further association after stratifying for age and treatment group. A meta-analysis of 18 studies, including our own, showed an increased risk of breast cancer in premenopausal women with 677TT genotype, with an odds ratio of 1.42 (95% CI, 1.02–1.98).
Our study lends support to a positive association between the MTHFR variant homozygous allele 677TT and breast cancer risk. Additional studies are warranted to provide further insight into the role of folate metabolism deficiency and breast cancer.
- Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis
Breast Cancer Research and Treatment
Volume 106, Issue 2 , pp 263-271
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Methylenetetrahydrofolate reductase
- Nested case-control study
- Industry Sectors
- Author Affiliations
- 1. Division of Chemoprevention, European Institute of Oncology, Milan, Italy
- 2. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
- 3. Niguarda Hospital, Milan, Italy
- 4. Ospedale San Camillo Forlanini, Rome, Italy
- 5. Istituto per lo Studio e la Cura dei Tumori “Fondazione Pascale”, Naples, Italy
- 6. Centro per lo Studio e la Prevenzione Oncologica, Florence, Italy
- 7. Ospedale G.B. Morgani, Forli, Italy
- 8. Fondazione Maugeri, Pavia, Italy
- 9. SC Oncologia Medica e Preventiva, E.O. Ospedali Galliera, Mura delle Cappuccine 14, 16128, Genoa, Italy